Elboga, UmutKalender, EbuzerYalcin, Hulya2024-09-192024-09-1920141179-1586https://doi.org/10.2147/RMI.S39098https://hdl.handle.net/20.500.12483/14183Tumor necrosis factor alpha (TNF-?) has a role in the pathogenesis of several inflammatory diseases such as rheumatoid arthritis, Crohn's disease, and ulcerative colitis. As TNF-? plays a role in the pathogenesis of different inflammatory diseases, anti-TNF-? agents (monoclonal antibodies [mAbs]) such as infliximab, adalimumab, and certolizumab have been developed and investigated for the treatment of these conditions. In recent years, these mAbs also have been used for diagnosis, monitoring, follow-up of disease activity, and therapy decision-making for inflammatory diseases, especially rheumatoid arthritis, after labeling with 99mTc. However, 99mTc-anti-TNF-? imaging might have severe adverse effects and is expensive. In contrast, scintigraphic imaging before therapy with radiolabeled mAbs may be a cost-effective solution for therapy decisions. © 2014 Elboga et al.eninfo:eu-repo/semantics/openAccessTc tumor necrosis factor-? imagingmAbMonoclonal antibodiesNuclear medicineReview Article711310.2147/RMI.S390982-s2.0-84892387229Q3